Malignant
How Bad Policy and Bad Evidence Harm People with Cancer
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
Für 20,95 € kaufen
Sie haben kein Standardzahlungsmittel hinterlegt
Es tut uns leid, das von Ihnen gewählte Produkt kann leider nicht mit dem gewählten Zahlungsmittel bestellt werden.
-
Gesprochen von:
-
Vinayak K. Prasad
-
Von:
-
Vinayak K. Prasad
Über diesen Titel
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel, but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful.
In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad discusses about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced.
Throughout this audiobook, Prasad illuminates deceptive practices, which:
- Promote novel cancer therapies long before credible data are available to support such treatment
- Exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars
Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings - our policies, our standards of evidence, and our drug regulation - incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices.
He takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price.
Ultimately, Prasad says:
- More cancer clinical trials should measure outcomes that actually matter to people with cancer.
- Patients on those trials should look more like actual global citizens.
- We need drug regulators to raise, not perpetually lower, the bar for approval.
- We need unbiased patient advocates and experts.
This well-designed, opinionated, and engaging audiobook explains what we can do differently to make serious and sustained progress against cancer and how we can avoid repeating the policy and practice mistakes of the past.
PLEASE NOTE: When you purchase this title, the accompanying PDF will be available in your Audible Library along with the audio.
©2020 Vinayak K. Prasad (P)2020 Vinayak K. PrasadDas sagen andere Hörer zu Malignant
Nur Nutzer, die den Titel gehört haben, können Rezensionen abgeben.Rezensionen - mit Klick auf einen der beiden Reiter können Sie die Quelle der Rezensionen bestimmen.
-
Gesamt
-
Sprecher
-
Geschichte
- Balancius
- 09.11.2023
Awesome Book, very well researched and explained
This book is, in my opinion, a must for everyone involved in patient care. The gathered knowledge about cancer patients, that is talked about in this book, can easily be translated to every other patient in medicine. Absolutely stunning
Ein Fehler ist aufgetreten. Bitte versuche es in ein paar Minuten noch einmal.
Sie haben diese Rezension bewertet.
Wir haben Ihre Meldung erhalten und werden die Rezension prüfen.